Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Ahn

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Leukemia & Lymphoma|March 3, 2021
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 studySanjal Desai, Clifton Mo, Erika M Gaglione, et al.
Blood|February 28, 2018
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 studyInhye E Ahn, Mohammed Z H Farooqui, Xin Tian, et al.
Blood Neoplasia|December 24, 2025
Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockadeReid W Merryman, Justin Kline, Robert A Redd, et al.
Annals of Hematology|October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphomaReid W Merryman, Robert A Redd, Arnold S Freedman, et al.
The Journal of Experimental Medicine|January 6, 2018
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemiaErika Tissino, Dania Benedetti, Sarah E M Herman, et al.
Hemasphere|January 30, 2023
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular LymphomaReid W Merryman, Laure Michaud, Robert Redd, et al.
Blood Advances|April 3, 2025
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemiaJames T Yoon, Yinglu Zhou, Mariia Mikhaleva, et al.
Blood Cancer Discovery|November 15, 2021
Overcoming Acquired Epigenetic Resistance to BTK InhibitorsArthur L Shaffer, James D Phelan, James Q Wang, et al.
Blood|July 23, 2021
COVID-19 in patients with CLL: improved survival outcomes and update on management strategiesLindsey E Roeker, Toby A Eyre, Meghan C Thompson, et al.
Blood Advances|October 24, 2025
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLLThomas Chatzikonstantinou, Mariia Mikhaleva, Christian Brieghel, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Leukemia & Lymphoma|March 3, 2021
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 studySanjal Desai, Clifton Mo, Erika M Gaglione, et al.
Blood|February 28, 2018
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 studyInhye E Ahn, Mohammed Z H Farooqui, Xin Tian, et al.
Blood Neoplasia|December 24, 2025
Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockadeReid W Merryman, Justin Kline, Robert A Redd, et al.
Annals of Hematology|October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphomaReid W Merryman, Robert A Redd, Arnold S Freedman, et al.
The Journal of Experimental Medicine|January 6, 2018
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemiaErika Tissino, Dania Benedetti, Sarah E M Herman, et al.
Hemasphere|January 30, 2023
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular LymphomaReid W Merryman, Laure Michaud, Robert Redd, et al.
Blood Advances|April 3, 2025
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemiaJames T Yoon, Yinglu Zhou, Mariia Mikhaleva, et al.
Blood Cancer Discovery|November 15, 2021
Overcoming Acquired Epigenetic Resistance to BTK InhibitorsArthur L Shaffer, James D Phelan, James Q Wang, et al.
Blood|July 23, 2021
COVID-19 in patients with CLL: improved survival outcomes and update on management strategiesLindsey E Roeker, Toby A Eyre, Meghan C Thompson, et al.
Blood Advances|October 24, 2025
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLLThomas Chatzikonstantinou, Mariia Mikhaleva, Christian Brieghel, et al.
Pageof 13